Endogenous opioid peptides and chronic liver disease: From bedside to bench

Journal of Hepatology

Volumn 46, Issue 4, 2007, Pages 583-586

  Marzioni, Marco ^a   Svegliati Baroni, Gianluca ^a   Alpini, Gianfranco ^b   Benedetti, Antonio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE; OPIATE; PEPTIDE;

ARTICLE; CHOLESTASIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; LIVER CELL; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS;

ANIMALS; CHOLESTASIS; CHRONIC DISEASE; ENDORPHINS; HUMANS; LIVER DISEASES; PRURITUS;

EID: 33947262609     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.01.006     Document Type: Article

References (39)

1. Jones E.A., and Bergasa N.V. The pruritus of cholestasis. Hepatology 29 (1999) 1003-1006
2. Bergasa N.V., Thomas D.A., Vergalla J., Turner M.L., and Jones E.A. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 53 (1993) 1253-1257
3. Bergasa N.V., Liau S., Homel P., and Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 22 (2002) 107-113
4. Bernstein J.E., and Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 115 (1979) 1366-1367
5. Kaplan M.M., and Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 353 (2005) 1261-1273
6. Summerfield J.A. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 10 (1980) 180-183
7. Bergasa N.V., Schmitt J.M., Talbot T.L., Alling D.W., Swain M.G., Turner M.L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27 (1998) 679-684
8. Bergasa N.V., Alling D.W., Talbot T.L., Wells M.C., and Jones E.A. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 41 (1999) 431-434
9. Wolfhagen F.H., Sternieri E., Hop W.C., Vitale G., Bertolotti M., and Van Buuren H.R. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 113 (1997) 1264-1269
10. Thomas D.A., Williams G.M., Iwata K., Kenshalo Jr. D.R., and Dubner R. Effects of central administration of opioids on facial scratching in monkeys. Brain Res 585 (1992) 315-317
11. Nelson L., Vergnolle N., D'Mello C., Chapman K., Le T., and Swain M.G. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol 44 (2006) 1141-1149
12. Thornton J.R., and Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ 297 (1988) 1501-1504
13. Swain M.G., Rothman R.B., Xu H., Vergalla J., Bergasa N.V., and Jones E.A. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 103 (1992) 630-635
14. Bergasa N.V., Rothman R.B., Vergalla J., Xu H., Swain M.G., and Jones E.A. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 15 (1992) 220-224
15. Jones E.A., Neuberger J., and Bergasa N.V. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 95 (2002) 547-552
16. Jones E.A., and Dekker L.R. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 118 (2000) 431-432
17. Lazaridis K.N., Strazzabosco M., and LaRusso N.F. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 127 (2004) 1565-1577
18. Bergasa N.V., Sabol S.L., Young III W.S., Kleiner D.E., and Jones E.A. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 268 (1995) G346-G354
19. Glasel J.A. The effects of morphine on cell proliferation. Prog Drug Res 55 (2000) 33-80
20. Zagon I.S., Smith J.P., and McLaughlin P.J. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 14 (1999) 577-584
21. Zagon I.S., Hytrek S.D., and McLaughlin P.J. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 271 (1996) R511-R518
22. Zagon I.S., Wu Y., and McLaughlin P.J. Opioid growth factor is present in human and mouse gastrointestinal tract and inhibits DNA synthesis. Am J Physiol 272 (1997) R1094-R1104
23. Simon E.J. Opioid receptors and endogenous opioid peptides. Med Res Rev 11 (1991) 357-374
24. Wollemann M., and Benyhe S. Non-opioid actions of opioid peptides. Life Sci 75 (2004) 257-270
25. Glaser S., Benedetti A., Marucci L., Alvaro D., Baiocchi L., Kanno N., et al. Gastrin inhibits cholangiocyte growth in bile duct-ligated rats by interaction with cholecystokinin-B/Gastrin receptors via d-myo-inositol 1,4,5-triphosphate-, Ca(2+)-, and protein kinase C alpha-dependent mechanisms. Hepatology 32 (2000) 17-25
26. Gigliozzi A., Alpini G., Svegliati Baroni G., Marucci L., Metalli V.D., Glaser S., et al. Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology 127 (2004) 1198-1209
27. LeSage G., Alvaro D., Benedetti A., Glaser S., Marucci L., Eisel W., et al. Cholinergic system modulates growth, apoptosis and secretion of cholangiocytes from bile duct ligated rats. Gastroenterology 117 (1999) 191-199
28. LeSage G.D., Alvaro D., Glaser S., Francis H., Marucci L., Roskams T., et al. Alpha-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca(2+)- and PKC-dependent stimulation of cAMP. Hepatology 40 (2004) 1116-1127
29. LeSage G.D., Marucci L., Alvaro D., Glaser S., Benedetti A., Marzioni M., et al. Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity. Hepatology 36 (2002) 641-651
30. Marzioni M., Glaser S., Francis H., Marucci L., Benedetti A., Alvaro D., et al. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 128 (2005) 121-137
31. Tietz P.S., Alpini G., Pham L.D., and LaRusso N.F. Somatostatin inhibits secretin-induced ductal hypercholeresis and exocytosis by cholangiocytes. Am J Physiol 269 (1995) G110-G118
32. Alvaro D., Alpini G., Onori P., Perego L., Svegliata Baroni G., Franchitto A., et al. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 119 (2000) 1681-1691
33. Roskams T., van den Oord J.J., De Vos R., and Desmet V.J. Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol 137 (1990) 1019-1025
34. Marzioni M., Alpini G., Saccomanno S., de Minicis S., Glaser S., Francis H., et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology 130 (2006) 1831-1847
35. Gallate J.E., Mallet P.E., and McGregor I.S. Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. Psychopharmacology (Berl) 173 (2004) 210-216
36. Ebrahimkhani M.R., Kiani S., Oakley F., Kendall T., Shariftabrizi A., Tavangar S.M., et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 55 (2006) 1606-1616
37. Pinzani M. Cholestasis and fibrogenesis. In: Alpini G., Alvaro D., Marzioni M., LeSage G., and LaRusso N. (Eds). The pathobiology of biliary epithelia (2004), Landes Biosciences, Georgetown (TX) 211-219
38. Svegliati-Baroni G., De Minicis S., Marzioni M., Casini A., Salzano R., Saccomanno S., et al. Endogenous opioids stimulate HSC activity in a paracrine manner during the development of liver fibrosis. J Hepatol 44 (2006) S43
39. Smith J.P., Conter R.L., Bingaman S.I., Harvey H.A., Mauger D.T., Ahmad M., et al. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs 15 (2004) 203-209